NICE
NICE changes stance on Lilly’s breast cancer dug Verzenios
Phil Taylor
breast cancer, Eli Lilly, NHS, NICE, Oncology, Verzenio
0 Comment
Scotland backs Bavencio for bladder cancer after NICE says no
Phil Taylor
Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma
0 Comment
Patients/ Views & Analysis/ Views and analysis
How to balance the patient voice atop the shifting plates of HTA
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme
Phil Taylor
bimekizumab, dermatology, HEOR, NICE, psoriasis, UCB
0 Comment
NICE changes its mind on rare bile duct cancer drug from Incyte
Phil Taylor
cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology
0 Comment
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’
Phil Taylor
Johnson & Johnson, NICE, Oncology, Prostate cancer, The Institute of Cancer Research, Zytiga
0 Comment